Key Highlights
- Cytek Biosciences is a penny stock: shares were flat at last closing at $4.70 per share.
- Revenue of roughly $48 million rose around 6% year over year on instrument sales in the US and China and higher service revenue.
- The net loss widened to around $12 million from a smaller loss a year earlier, with GAAP gross Margin aided by a one-time Tariff refund.
- The company raised its full-year Revenue guidance only slightly and held substantial cash and marketable securities.
Cytek Biosciences, Inc. (NASDAQ:CTKB), a penny stock, was flat at last closing. Cytek is a life-science tools maker specializing in full-spectrum flow-cytometry instruments and related reagents and services.
This is a genuinely quiet small-cap, with modest revenue growth, a widening net loss, and guidance raised only slightly, reflecting a slow, still-loss-making tools recovery rather than a hidden breakout.
Latest Developments
In its most recent quarter, Cytek reported revenue of roughly $48 million, up around 6% year over year on instrument sales in the US and China and higher service revenue, but its net loss widened to around $12 million from a smaller loss a year earlier. GAAP gross margin was aided by a one-time tariff refund, and Recurring Revenue was a growing share of the total, with the installed base of instruments expanding. The company raised its full-year revenue guidance only slightly and held substantial cash and marketable securities. It launched a new flagship instrument and new configurations.
Financial and Business Position
The financial position combines a strong cash cushion with a still-loss-making income statement. Revenue growth was modest at around 6%, the net loss widened, so the company remains unprofitable. The positives are incremental: new product launches, growing recurring revenue, an expanding installed base, and a large cash and securities balance that reduces financing risk.
Stock-Market Context
Cytek shares closed at $4.70 at last closing, unchanged. The company is a small-cap with a Market Value under a billion dollars, still unprofitable on a trailing basis, and a mixed buy-to-hold analyst consensus with a target around $5.50.
What Investors Should Watch
Investors should watch revenue growth and whether it accelerates, the trajectory of the net loss toward profitability, recurring revenue and the installed base, and the adoption of the new instruments, along with the cash cushion.






Please wait processing your request...